Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.64 +0.05 (+0.32%)
Streaming Delayed Price Updated: 11:29 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric... 
Via MarketMinute
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results... 
Via MarketMinute
Topics Intellectual Property
News headline image
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies ↗
The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 
Via Stocktwits
News headline image
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results. 
Via Benzinga
News headline image
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges ↗
Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairment charges weigh on revenue and profit. 
Via Benzinga
News headline image
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact ↗
Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential success-based milestones. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio. 
Via Benzinga
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
News headline image
What's Going On With Nano-Cap Galecto Stock On Tuesday? ↗
Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and clinical priorities. 
Via Benzinga
News headline image
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
5 Best High-Yield Dividend Stocks to Buy Now ↗
These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn. 
Via The Motley Fool
News headline image
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
What's Going On With Takeda Stock On Friday? ↗
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro. 
Via Benzinga
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales ↗
Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and rare disease drugs. 
Via Benzinga
News headline image
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.